Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
US Department of Justice
McKinsey
UBS
AstraZeneca
Johnson and Johnson
Novartis
Queensland Health
Healthtrust

Generated: August 21, 2017

DrugPatentWatch Database Preview

DANTRIUM Drug Profile

« Back to Dashboard

What is the patent landscape for Dantrium, and when can generic versions of Dantrium launch?

Dantrium is a drug marketed by Par Sterile Products and is included in two NDAs.

The generic ingredient in DANTRIUM is dantrolene sodium. There are five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.

Summary for Tradename: DANTRIUM

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list58
Clinical Trials: see list1
Patent Applications: see list2,023
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DANTRIUM at DailyMed

Pharmacology for Tradename: DANTRIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
INJECTABLE;INJECTION018264-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-003Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DANTRIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
INJECTABLE;INJECTION018264-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Citi
Covington
Boehringer Ingelheim
Johnson and Johnson
Julphar
Accenture
Express Scripts
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot